News & Events

Blog

  • October 25, 2016
    Posted by: Jamie Zacher, PharmD

    Patient engagement is crucial for any clinical trial to have good, reliable and robust data. The challenge, therefore, is to keep patients engaged and feeling valued because patients who are not engaged and are not feeling valued, are more likely to drop out.  And drop outs costs the sponsor company additional time, money and resources to complete their […]

  • October 18, 2016
    Posted by: Jamie Zacher, PharmD

    Every patient that drops out of a clinical trial costs the study sponsor time and money.  According to research by the Tufts Center for the Study of Drug Development, only one-half of patients randomized into a clinical trial go to completion.[1] When a patient drop out and is lost to follow-up, new patients must be […]

  • October 11, 2016
    Posted by: Joe Martinez, RPh, PDE, PPC

    This is Part 3 and the final blog of a three-part blog series that highlights the challenges and opportunities of driving drug development through the lens of the clinical operations team and senior management. We discussed the current breakdown of costs in Driving Innovation Blog Part 1 and Utilizing Technology and Maximizing Resources in Part […]

  • October 4, 2016
    Posted by: Joe Martinez, RPh, PDE, PPC

    This is Part 2 of a three-part blog series that will highlight the challenges and opportunities of driving drug development through the lens of the clinical operations team and senior management. We discussed the current breakdown of costs in Driving Innovation Blog Part 1. In Part 2 we discuss considerations for utilizing technology and maximizing […]

  • September 27, 2016
    Posted by: Joe Martinez, RPh, PDE, PPC

    This is a three-part blog  that will highlight the challenges and opportunities of driving drug development through the lens of the clinical operations team and senior management.  We’ll discuss what the current breakdown of costs is, how you can immediately compile robust and meaningful data, and how to communicate (aka publish) this data to your […]

  • September 20, 2016
    Posted by: Joe Martinez, RPh, PDE, PPC

    In the last two Center Point Blog Tuesdays, we addressed the first two keys necessary to unlock market access: building and refining an overall market access strategy and developing and creating compelling clinical and medical evidence. Today, in the final post of this three part series, we turn our focus on how to best communicate […]

  • September 13, 2016
    Posted by: Joe Martinez, RPh, PDE, PPC

    In last week’s blog, we identified the three keys required to unlock market access. These include: 1)     building and refining an overall market access strategy 2)     developing and creating compelling clinical and medical evidence 3)     effectively communicating the value that matters to your internal and external stakeholders We also explored how to devise an effective […]

  • September 6, 2016
    Posted by: Joe Martinez, RPh, PDE, PPC

    Market Access depends on the answers to two very important questions: What is your product’s story? And, how do decision-makers perceive your product’s value proposition? The spotlight is on the word “perceive”, as positive perception is crucial to achieving the end goal of market access and utilization. It is also essential to bear in mind […]

  • August 30, 2016
    Posted by: Tina Schlecht, PharmD, MBA

    Twenty years ago, Dr. John Urquhart published a paper titled, “Patient Non-Compliance with Drug Regimens: Measurement, Clinical Correlates, Economic Impact.” In his paper, Urquhart raises the alarm about patient non-compliance with medications and its implications for clinical trial outcomes. He argued that, by ignoring under-dosing due to medication non-compliance, sponsors can draw the false conclusion […]

  • August 23, 2016
    Posted by: Jamie Zacher, PharmD

    According to a report published by the IMS Institute for Healthcare Informatics in July, the cost of treating those with type 2 diabetes was $176 billion in 2012, with diabetes-related complications accounting for around 61% of the cost(1). These complications, such as vision problems, kidney issues, cardiovascular disease, nerve damage, and toe and foot amputations, […]

  • Case Study
    A Biopharmaceutical Company Sponsoring a Phase II Clinical Trial in the U.S.
    read more...
  • Latest News
    Center Point Clinical Services Names Gerald E. Finken New CEO
    March 15, 2018
    read more...
  • Need More Information?